Core Insights - The opening price of Yaojie Ankang on its first trading day was HKD 21.65 per share, representing a 64.64% increase from the IPO price, and it closed at HKD 23.50 per share, a rise of 78.71%, with a market capitalization of approximately HKD 9.3 billion [2] - The company experienced over-subscription in its public offering, achieving a 25.92 times subscription rate in the Hong Kong public offering phase, while the international offering had a subscription rate of only 0.98 times [2] - Yaojie Ankang is a clinical demand-driven biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular diseases [4] Company Overview - Founded in April 2014, Yaojie Ankang was previously known as Nanjing Yaojie Ankang Biotechnology Co., Ltd., with a registered capital of approximately RMB 380 million [2] - The company has developed a pipeline that includes one core product and five clinical-stage candidates, along with one preclinical candidate [4] - The core product, Tinengotinib, is a unique multi-target kinase inhibitor aimed at three key pathways and is currently undergoing two pivotal registration clinical trials for treating cholangiocarcinoma that has progressed after FGFR inhibitor treatment [4] Financial Performance - In 2023 and 2024, Yaojie Ankang recorded net losses of approximately RMB 343.39 million and RMB 274.61 million, respectively [5] - The research and development costs for 2023 and 2024 were approximately RMB 344.48 million and RMB 244.00 million, accounting for 89.8% and 83.6% of total operating expenses, respectively [4][5] - The company incurred significant expenses related to contract research organizations (CRO), with costs of approximately RMB 192 million in 2023 and RMB 146 million in 2024, primarily attributed to the development of Tinengotinib [4]

转自：PharmaBlock药石科技 【中国，南京，2025年6月23日】药捷安康（南京）科技股份有限公司（「药捷安康」或「公司」；股 份代号：2617.HK），今日正式于香港联合交易所有限公司（「联交所」）主板挂牌上市。公司管理层 代表及重要嘉宾共同出席上市仪式，敲响了开市锣，标志着公司迈入资本市场的崭新阶段。 祝贺参股公司药捷安康（南京）科技股份有限公司在香港交易所成功上市！作为药捷安康的股东与合作 伙伴，药石科技始终关注并支持其创新研发的成长轨迹。我们欣喜见证药捷安康在吴永谦博士的领导 下，凭借卓越的技术实力迈向国际资本市场，期待其以港股上市为契机，加速全球商业化进程，为患者 带来更多突破性治疗方案。 【免责】 本新闻稿中提供的信息包含前瞻性陈述，其中涉及许多已知和未知的风险、不确定性和假设。此处包含 的前瞻性陈述反映了药捷安康（南京）科技股份有限公司截至本新闻稿发布之日的判断和观点。此类前 瞻性陈述既不是承诺也不是保证，而是受到各种风险和不确定性的影响，其中许多风险和不确定性超出 了我们的控制范围，或可能无法实现，并且可能导致实际结果与这些前瞻性陈述中的预期结果存在重大 差异。我们明确表示不承担任何义 ...

Core Viewpoint - The company,药捷安康, is set to launch an IPO with a global offering of 15.281 million H-shares at a price of HKD 13.15 per share, aiming to raise approximately HKD 201 million, with listing expected on June 23, 2025 [1][3]. Company Overview -药捷安康, established in April 2014, focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular diseases [5]. - The company has developed a pipeline that includes one core product and five clinical-stage candidates, along with one preclinical candidate [5]. Financial Highlights - The total amount raised from cornerstone investors is approximately HKD 149 million, with notable investors including Jiangbei Pharmaceutical and Kangfang Biotech [3]. - For the years 2023 and 2024, the company reported net losses of approximately RMB 343.39 million and RMB 274.61 million, respectively [7]. Research and Development - The core product, Tinengotinib, is a multi-target kinase inhibitor currently undergoing two pivotal clinical trials for cholangiocarcinoma [5][6]. - The R&D costs for 2023 and 2024 are estimated at RMB 344.75 million and RMB 244.00 million, representing 89.8% and 83.6% of total operating expenses, respectively [6].

Core Viewpoint - The company,药捷安康, is undergoing a listing process on the Hong Kong Stock Exchange, with a focus on developing innovative therapies for cancer and other diseases, while currently not generating any revenue from product sales [1][4][7]. Company Overview - 药捷安康 is a biopharmaceutical company focused on discovering and developing small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [4]. - The company has developed a core product, Tinengotinib (TT00420), which is a multi-target kinase (MTK) inhibitor targeting key pathways including FGFR/VEGFR, JAK, and Aurora kinases [4]. Clinical Development - Tinengotinib is currently undergoing two pivotal/registration clinical trials for cholangiocarcinoma (CCA) in patients who have progressed after FGFR inhibitor treatment, with one trial in China and another involving the US [4]. - The company is also exploring Tinengotinib for other indications such as metastatic castration-resistant prostate cancer (mCRPC), breast cancer, and hepatocellular carcinoma (HCC) [5]. Market Potential - The global CCA drug market is projected to reach $2 billion by 2024, with a compound annual growth rate (CAGR) of 16.2% from 2019 to 2024, and further growth expected to $3.2 billion by 2027 [4]. Financial Performance - The company reported revenues of approximately 1.18 million RMB in 2023, with no revenue expected in 2024, and incurred significant operating losses of 343.39 million RMB and 274.61 million RMB for the respective years [7][9]. - The financial data indicates that the company has not yet achieved profitability and relies on milestone payments from partnerships for revenue [7].

2024 年 12 月 20 日，中国证监会国际合作司披露了《关于药捷安康（南京）科技股份有限公司境 外发行上市及境内未上市股份"全流通"备案通知书》。 药捷安康专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。公司主要开发全球范围内同 类首创及同类最佳药物，目前管线有6款临床阶段候选产品及一种临床前阶段候选产品。其中，核心 产品Tinengotinib（TT-00420）处于注册临床阶段。 | 候团览物! | 肥盛/模制 | (新闻) | II =/ 刷合 | | | 用用和身 | | 颜期即將來區的雪配碑* | 商量化幅利* | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 图库的 | IND 7 /6 | III. 玩 | 圖就作用開/加點 | | | | | | 喷管编 FGF安排加新费用式 | M- | of a result of the property. | | | 國家德基督管 管理局= | 於2025年下半年完成試驗 | | | | | 都合(2)34.) | M- M- | FRANC ...